Please select the option that best describes you:

Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?  

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution